Bio-Matrix Scientific Group, Inc. 10-QSB
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-QSB

Quarterly Report under Section 13 or 15 (d) of
Securities Exchange Act of 1934

For Period ended March 31, 2007

Commission File Number 0-32201

BIO MATRIX SCIENTIFIC GROUP, INC.
(Exact name of registrant as specified in its charter)
 
DELAWARE
33-0824714
(State of Incorporation)
(I.R.S. Employer Identification No.)
 
 
 
 
8885 Rehco Road, San Diego, California
92121
(Address of Principal Executive Offices)
(Zip Code)

(619) 398-3517
(Registrant's telephone number, including area code)
 


Check whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes [X] No [ ]

There were 19,295,042 shares of Common Stock outstanding as of April 5, 2007.
 
 



1
 
Chang G. Park, CPA, Ph. D.
t 371 E STREET t CHULA VISTA t CALIFORNIA 91910-2615t
t TELEPHONE (858)722-5953 t FAX (858) 408-2695 t FAX (858) 764-5480
t E-MAIL changgpark@gmail.com t


Report of Independent Registered Public Accounting Firm


To the Board of Directors of
Bio-Matrix Scientific Group, Inc. and Subsidiary
(Formerly Tasco International, Inc.)
(A Development Stage Company)


We have reviewed the consolidated accompanying balance sheet of Bio-Matrix Scientific Group, Inc. and Subsidiary (Formerly Tasco International, Inc) (A Development Stage “Company”) as of March 31, 2007, and the related consolidated statements of operation, changes in stockholders’ equity, and cash flows for the six months and three months ended March 31, 2007; and for the period from October 6, 1998 (inception) through March 31, 2007. These financial statements are the responsibility of the Company’s management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures to financial data and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the consolidated financial statements referred to above for them to be in conformity with generally accepted accounting principles.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 5 to the consolidated financial statements, the Company is currently in the development stage. Because of the Company’s current status and limited operations there is substantial doubt about its ability to continue as a going concern. Management’s plans in regard to its current status are also described in Note 5. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
 


/s/Chang G Park
__________________________
Chang G. Park, CPA

May 8, 2007
Chula Vista, California


2
PART I.

BIO-MATRIX SCIENTIFIC GROUP, IINC. AND SUBSIDIARY
(FORMARLY TASCO INTERNATIONAL)
(A Development Stage Company)
Consolidated Balance Sheets
               
ASSETS
    
               
  
   
As of March 31, 2007 (Unaudited)
    
As of September 30, 2006
  
               
               
CURRENT ASSETS
              
Cash
 
$
147,705
 
$
22,641
 
Employee Receivable
   
3,000
       
Pre-paid Expenses
    
23,727
   
20,207
 
Total Current Assets
    
174,432
   
42,848
 
               
PROPERTY & EQUIPMENT
    
364,737
   
340,557
 
               
GOODWILL
              
               
Intangible Assets/Technology
    
-
       
               
Total Other Assets
    
25,726
   
29,127
 
                 
TOTAL ASSETS
  
$
564,895
 
$
412,532
 
           
               
               
LIABILITIES AND STOCKHOLDERS' EQUITY
    
               
               
CURRENT LIABILITIES
              
Accounts payable
  
$
3,945
 
$
91,079
  
Loans from former parent
    
-
   
1,195,196
 
Due To/ From New Parent
    
-
   
-
 
Notes Payable
    
321,562
   
148,952
 
Accrued Payroll
   
-
   
-
 
Accrued Payroll Taxes
   
14,545
   
16,460
 
Accrued Interest
    
13,258
   
1,368
 
Accrued expenses
    
-
   
-
 
               
               
Total Current Liabilities
    
353,310
   
1,453,055
 
               
LONG TERM LIABILITIES
    
-
   
-
 
TOTAL LIABILITIES
    
353,310
   
1,453,055
 
               
STOCKHOLDERS' EQUITY
              
Preferred Stock ($.0001 par value authorized
              
20,000,000 shares authorized; none
              
issued and outstanding.)
              
Common Stock, ($.0001 par value authorized
              
80,000,000 shares authorized; 17,996,619 and 13,385,000
           
shares issued and outstanding as of March 31, 2007 and September 30, 2006, respectively
    
1,800
   
1339
  
Additional paid in Capital
    
32,609,035
   
30,375,584
 
Deficit accumulated during the development stage
    
(32,399,250
)
  
(31,417,446
)
               
Total Stockholders' Equity (Deficit)
  
$
211,585
 
$
(1,040,523
)
               
TOTAL LIABILITIES
             
& STOCKHOLDERS' EQUITY
  
$
564,895
 
$
412,532
 
 
The accompanying notes are an integral part of these financial statements
3
 
BIO-MATRIX SCIENTIFIC GROUP, IINC. AND SUBSIDIARY
(FORMARLY TASCO INTERNATIONAL)
(A Development Stage Company)
Consolidated Statement of Operations
(Unaudited)
 
 
                                             
Inception
  
 
                                          
(October 6, 1998)
  
 
   
3 Months Ended
    
3 Months Ended
   
6 Months Ended
    
6 Months Ended
    
through
  
 
    
March 31,
    
March 31
   
March 31,
    
March 31
    
March 31,
  
     
2007
    
2006
    
2007
    
2006
    
2007
  
                                 
REVENUES
                                
Sales
  
$
-
  
$
-
  
$
-
 
$
-
  
$
1,000
 
Total Revenues
    
-
   
-
    
-
         
1,000
 
                                 
COSTS AND EXPENSES
    
-
                         
Research and Development
    
60,604
         
169,092
         
196,767
 
General and administrative
    
217,090
   
1,633
    
441,763
   
1,883
    
1,268,458
 
Depreciation and amortization
    
333
         
667
         
1,000
 
Consulting and professional fees
    
228,321
         
354,161
         
1,144,796
 
Impairment of goodwill & intangibles
    
-
         
-
         
29,777,222
 
                                  
Total Costs and Expenses
    
506,348
   
1,633
    
965,683
   
1,883
    
32,388,243
 
                                 
                                 
OPERATING LOSS
    
(506,348
)
  
(1,633
)
  
(965,683
)
  
(1,883
)
  
(32,387,243
)
                                 
OTHER INCOME & (EXPENSES)
                                
                                 
                                 
Interest Expense
    
(9,509
)
        
(16,354
)
        
(17,722
)
Other Expense
    
(73
)
  
1
    
(73
)
  
13
    
(73
)
Interest Income
    
306
         
306
         
345
 
Other income
    
-
         
-
         
5,443
 
                                 
Total Other Income & (Expenses)
    
(9,276
)
  
1
    
(16,121
)
  
13
    
(12,007
)
                                  
                                 
NET INCOME (LOSS)
  
$
(515,624
)
$
(1,632
)
  
(981,804
)
$
(1870
)
$
(32,399,250
)
                                 
                                 
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE
                                
                                  
BASIC AND DILUTED EARNINGS (LOSS) PER SHARE
  
$
(0.03
)
$
(0.00
)
  
(0.06
)
$
(0.00
)
$
-
 
                                  
WEIGHTED AVERAGE NUMBER OF
                                
COMMON SHARES OUTSTANDING
    
16,947,346
   
12,780,000
    
16,102,133
   
12.780,000
    
-
 
 
The accompanying notes are an integral part of these financial statements
4
BIO-MATRIX SCIENTIFIC GROUP INC. AND SUBSIDIARY
(FORMERLY TASCO INTERNATIONAL, INC.)
Consolidated Statement of Stockholders' Equity
From October 6, 1998 through March 31, 2007
(Unaudited)
 
 
    
   
   
Additional
    
Deficit Accumulated
    
 
 
  
Common
  
Paid-in
    
During the
   
 
 
    
Shares
    
Amount
    
Capital
    
Development Stage
    
Total
 
                     
 
                                 
Stock issued for cash October 6, 1998
    
1,000,000
 
$
100
 
$
(90
)
 $    
$
10
 
Stock issued for cash October 9, 1998
 
  
1,300,000
   
130
   
1,170
         
1,300
 
Stock issued for cash October 9, 1998
    
190,000
   
19
   
171
         
190
 
Stock issued for cash April 1, 1999
    
290,000
   
29
   
261
         
290
 
Net Loss October 6,1998 (inception)
                            
-
 
through September 30, 1999
                
(295
)
  
(295
)
Balance September 30, 1999
    
2,780,000
   
278
   
1,512
   
(295
)
  
1,495
 
 
                                
Stock issued for cash October 19, 1999
 
  
10,000,000
   
1,000
   
9,000
         
10,000
 
Net Loss October 1,1999
 
                          
-
 
through September 30, 2000
                
(367
)
  
(367
)
Balance September 30, 2000
    
12,780,000
   
1,278
   
10,512
   
(662
)
  
11,128
 
 
                                
Net Loss October 1, 2000
                            
-
 
through September 30, 2001
                
(11,028
)
  
(11,028
)
Balance September 30, 2001
    
12,780,000
   
1,278
   
10,512
   
(11,690
)
  
100
 
                                 
Net Loss October 1, 2001
                            
-
 
through September 30, 2002
                
(4,257
)
  
(4,257
)
Balance September 30, 2002
    
12,780,000
   
1,278
   
10,512
   
(15,947
)
  
(4,157
)
                                 
Net Loss October 1, 2002
                            
-
 
through September 30, 2003
                
(4,328
)
  
(4,328
)
Balance September 30, 2003
    
12,780,000
   
1,278
   
10,512
   
(20,275
)
  
(8,485
)
                                 
Contributed Capital
                
12,362
         
12,362
 
Net Loss October 1, 2003
                            
-
 
through September 30, 2004
                
(7,974
)
  
(7,974
)
Balance September 30, 2004
    
12,780,000
   
1,278
   
22,874
   
(28,249
)
  
(4,097
)
                                 
Contributed Capital
                
9,021
         
9,021
 
Net Loss October 1, 2004
                            
-
 
through September 30, 2005
                
(6,667
)
  
(6,667
)
Balance September 30, 2005
    
12,780,000
   
1,278
   
31,895
   
(34,916
)
  
(1,743
)
                                 
Stock Cancelled June 13, 2006
    
(10,000,000
)
  
(1,000
)
              
(1,000
)
Stock issued June 13, 2006
    
10,000,000
   
1,000
   
28,999,000
         
29,000,000
 
Stock issued for services
    
305,000
   
31
   
759,719
         
759,750
 
Stock issued for Compensation
    
300,000
   
30
   
584,970
         
585,000
 
Net Loss October 1, 2005
                            
-
 
through September 30, 2006
                      
(31,382,530
)
  
(31,382,530
)
Balance September 30, 2006
    
13,385,000
   
1,339
   
30,375,584
   
(31,417,446
)
  
(1,040,523
)
                                 
Stock issued for services
    
100,184
   
10
   
112,524
         
112,534
 
Stock issued for Compensation
    
153,700
   
15
   
101,465
         
101,480
 
Stock issued in exchange for canceling debt
    
2,854,505
   
284
   
1,446,120
         
1,446,404
 
Net Loss October 1, 2006
                            
-
 
through December 31, 2006
                      
(466,179
)
  
(466,179
)
Balance December 31, 2006
    
16,493,389
   
1,649
   
32,035,693
   
(31,883,625
)
  
153,717
 
                                 
Stock issued for cash
    
500,000
   
50
   
124,950
         
125,000
 
Stock issued for services
    
359,310
   
36
   
235,042
         
235,078
 
Stock issued for Compensation
    
143,920
   
14
   
88,400
         
88,414
 
Stock issued in exchange for canceling debt
    
500,000
   
50
   
124,950
         
125,000
 
Net Loss January 1, 2007
                            
-
 
through March 31, 2007
                      
(515,624
)
  
(515,624
)
Balance March 31, 2007
    
17,996,619
 
$
1,800
 
$
32,609,035
 
$
(32,399,249
)
$
211,585
 
 
The accompanying notes are an integral part of these financial statements
5
BIO-MATRIX SCIENTIFIC GROUP, INC. AND SUBSIDIARY
(FORMERLY TASCO INTERNATIONAL, INC.)
( A Development stage Company)
Consolidated Statements of Cash Flows
(Unaudited)
 
 
                           
October 6, 1998
  
 
                            
(inception)
  
 
    
6 Months Ended
    
6 Months Ended
    
3 Months Ended
    
3 Months Ended
    
through
  
 
    
March 31,
    
March 31,
    
March 31,
    
March 31,
    
March 31,
  
     
2007
    
2006
    
2007
    
2006
    
2007
  
                                 
CASH FLOWS FROM OPERATING ACTIVITIES
                                
                                 
Net (loss)
  
$
(981,804
)
$
(1,870
)
$
(515,624
)
  
(1,632
)
$
(32,399,250
)
Adjustments to reconcile net loss to net cash (used in) provided
                                
by operating activities:
                                
Impairment of goodwill and intangible asset
    
-
                     
29,777,222
  
                                 
Depreciation expense
    
667
   
-
   
333
   
-
   
1,000
  
                                 
Stock issued for compensation
    
189,894
   
-
   
88,414
   
-
   
774,894
  
                                 
Stock issued for services
    
347,612
   
-
   
235,078
   
-
   
1,107,362
  
                                 
Cancellation of Debt
                            
(5,443
)
Stock issued to cancel debt plus accrued interest
    
376,209
         
125,000
         
376,209
 
Changes in operating assets and liabilities:
                      
-
       
                                 
(Increase) decrease in receivables
    
(3,000
)
        
(2,926
)
        
(3,000
)
(Increase) decrease in prepaid expenses
    
(3,520
)
        
(23,727
)
        
(23,727
)
Increase (Decrease) in Accounts Payable
    
(87,134
)
  
(1,600
)
  
(50,278
)
  
(1,600
)
  
3,945
  
Increase (Decrease) in Accrued Expenses
    
9,976
   
-
   
14,805
   
-
   
27,804
  
                                 
                                 
( Increase) Decrease in Deposits
    
3,401
         
3,401
         
(25,726
)
                                 
Net Cash Provided by (Used in) Operating Activities
    
(147,699
)
  
(3,470
)
  
(125,524
)
  
(3,232
)
  
(388,710
)
                                 
CASH FLOWS FROM INVESTING ACTIVITIES
                                
                                 
Purchases of fixed assets
    
(24,847
)
  
-
   
-
   
-
   
(365,737
)
Purchases of Intangible assets
          
-
   
-
   
-
   
(29,777,222
)
                                 
Net Cash Provided by (Used in) Investing Activities
    
(24,847
)
  
-
   
-
   
-
   
(30,142,959
)
                                 
CASH FLOWS FROM FINANCING ACTIVITIES
                                
                                 
Common stock issued for cash
    
50
         
50
         
1,328
  
                                 
Additional paid in Capital
    
124,950
   
-
   
124,950
   
-
   
29,161,288
  
                                 
Principal borrowings on notes
    
172,610
   
-
   
133,238
   
-
   
321,562
 
                                 
Net borrowings from related parties
    
-
   
3,500
   
-
   
-
   
1,195,196
 
                                 
Net Cash Provided by (Used in) Financing Activities
    
297,610
   
3,500
   
258,238
   
-
   
30,679,374
 
                                 
Net Increase (Decrease) in Cash
    
125,064
   
30
   
132,714
   
(3,232
)
  
147,705
 
                                 
Cash at Beginning of Period
    
22,641
   
-
   
14,991
   
3,261
   
-
 
                                 
Cash at End of Period
  
$
147,705
    
-
 
$
147,705
   
30
   
147,705
  
                                 
Supplemental Cash Flow Disclosures:
                                
                                 
Cash paid during period for interest
  
$
-
    
-
       
$
-
  
$
-
 
Cash paid during period for taxes
  
$
-
    
-
       
$
-
  
$
800
 
 
The accompanying notes are an integral part of these financial statements
6
BIO-MATRIX SCIENTIFIC GROUP, INC. AND SUBSIDIARY
(A Development Stage Company)
Notes to consolidated Financial Statements
As of March 31, 2007

NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS

Bio-Matrix Scientific Group, Inc. (“Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc.

The Company is in the development stage. From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet.

On June 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation (“BMSG”).

Bio-Matrix Scientific Group, Inc. is a development stage company in the business of designing, developing, and marketing medical devices, specifically disposable instruments used in stem cell extraction and tissue transfer procedures and operating cryogenic cellular storage facilities, specifically stem cell banking facilities. BMSG is the Company’s only subsidiary and operating entity at this time. On August 25, 2006, the Company amended its certificate of incorporation in order that it may change its name to Bio-Matrix Scientific Group, Inc.
 
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. BASIS OF ACCOUNTING

The consolidated financial statements have been prepared using the accrual basis of accounting. Under the accrual basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30, year-end.

B. USE OF ESTIMATES

The preparation of consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

C. DEVELOPMENT STAGE

The Company is a development stage company that, through its wholly owned subsidiary devotes substantially all of its efforts in the development of its plan to operate in the field of the development, manufacture and marketing of medical devices and the operation of cellular storage facilities, specifically stem cell banking facilities.
 
D. CASH EQUIVALENTS
 
The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.

E. PROPERTY AND EQUIPMENT 

Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.

The Company has depreciated property and equipment by the straight-line method over the useful life.
 
F. INCOME TAXES
 
7
 
Income taxes are provided in accordance with Statement of Financial accounting Standards No. 109 (SFAS 109), Accounting for Income Taxes. A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities.
Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion of all of the deferred tax assets will be not realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

G. BASIC EARNINGS (LOSS) PER SHARE

In February 1997, the FASB issued SFAS No. 128, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. SFAS No. 128 supersedes the provisions of APB No. 15, and requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of SFAS No. 128 effective October 6, 1998 (inception).

Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. Diluted earnings per share are the same as basic earnings per share due to the lack of dilutive items in the Company.

H. VALUATION OF GOODWILL

In accordance with SFAS No. 142, goodwill and other intangible assets with indefinite lives are not amortized, they are instead tested for impairment annually or whenever events or changes in circumstances indicate that the asset may be impaired. The Company performed an evaluation of goodwill and intangible assets in the fourth quarter of the twelve months ended September 30, 2006 which resulted in impairment charges of $29,777,222. The Company currently has $0 of goodwill.
 
NOTE 3. Property and equipment
 
Property and equipment as of March 31, 2007 consists of the following:

Acquisition cost:
      
Production Equipment
  
US$
93,315
  
Production Cleanroom
    
78,264
  
Leasehold improvement
    
188,981
  
Office equipment
    
3,057
  
Computer
    
2,120
  
 
      
Subtotal
    
365,737
  
Less accumulated depreciation
    
(1000
)
Total
  
US$
364,737
  
 
NOTE 4. WARRANTS AND OPTIONS

On July 17, 2006 the Company signed a public relations agreement with OTCFN which called for the issuance of an option agreement for 200,000 options exercisable at $4.50 per share. These options expired unexercised six months from the date of execution of the agreement
 
NOTE 5. GOING CONCERN

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company generated net losses of $32,399,250 during the period from October 6, 1998 (inception) through March 31, 2007. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds through debt or equity offerings. Management has yet to decide what type of offering the Company will use or how much capital the Company will raise. There is no guarantee that the Company will be able to raise any capital through any type of offerings.
8
NOTE 6. INCOME TAXES

 
    
As of March 31, 2007
  
Deferred tax assets:
      
Net operating tax carry forwards
  
$
11,015,745
  
Other
    
0
  
 
      
Gross deferred tax assets
    
11,,015,745
  
Valuation allowance
    
(11,015,745
)
 
      
Net deferred tax assets
  
$
0
  
 
Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a valuation allowance. In addition, the acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change.

NOTE 7. SCHEDULE OF NET OPERATING LOSSES

1998 Net Operating Loss
  
$
(295
)
1999 Net Operating Loss
    
(367
)
2000 Net Operating Loss
    
(11,028
)
2001 Net Operating Loss
    
(4,257
)
2002 Net Operating Loss
    
(4,328
)
2003 Net Operating Loss
    
(7,974
)
2004 Net Operating Loss
    
(6,667
)
2005 Net Operating Loss
    
(31,382,530
)
 Three Months Ended December 31, 2006 Net Operating Loss
    
(466,179
)
Three Months Ended March 31, 2007 Net Operating Loss
    
(515,624
)
Net Operating Loss
  
$
(32,399,250
)
 
As of March 31, 2007 the Company has a net operating loss carryforward of approximately $32,399,250 which will expire 20 years from the date the loss was incurred.

NOTE 8. RELATED PARTY TRANSACTION

Until July 3, 2006, a former director has provided office services without charge. Such costs are immaterial to the financial statements and, accordingly, have not been reflected therein.

The Company was loaned $5,300 from a related party without repayment terms and with no interest being charged. This Loan was forgiven as part of the Purchase Agreement involving the Company’s purchase of Bio-Matrix Scientific Group Inc. (Nevada).

On July 3, 2006, the Company acquired 100% of the share capital of BMSG from BMXP Holdings, Inc., formerly named Bio Matrix Scientific Group, Inc. (See Note 12).

David R. Koos, the Chairman, CEO and President of the Company, is, and at the time of the acquisition was, the Chairman and Chief Executive Officer of BMXP Holdings Inc. as well as beneficial owner of 24% of the share capital of BMXP Holdings, Inc. Brian Pockett, Vice President, COO and Director of the Company, is , and at the time of the acquisition was, Chief Operating Officer, Managing Director and a Director of BMXP Holdings Inc. as well as beneficial owner of 14% of the share capital of BMXP Holdings, Inc.
9
On October 11, 2006, the Company entered into an Agreement with BMXP Holdings, Inc (“BMXP”) (“Agreement”) pursuant to which the Company issued to BMXP 1,462,570 common shares of the Company on or prior to October 12, 2006. This issuance will constitute full satisfaction of the amount of $1,191,619 plus any accrued and unpaid interest, owed to BMXP by the Company.

As further consideration to BMXP for entering into this Agreement and abiding by the terms and conditions thereof, at any time within a period of 365 days from the date of the Agreement, BMXP shall have the right, upon written demand to the Company (“Registration Demand”), to cause the Company, within ninety days of the Registration Demand, to prepare and file with the United States Securities and Exchange Commission (“SEC”) a registration statement to register under the Securities Act of 1933, as amended, 11,462,570 common shares of the Company (including the shares issued pursuant to this Agreement) owned by BMXP (“Registerable Securities”), in order that the Registerable Securities may be distributed to BMXP shareholders on a pro rata basis ( based on their ownership of common shares of the Company as of a Record Date to be determined by BMXP), and use its reasonable best efforts to cause that registration statement to be declared effective by the SEC. This right may also be exercised by any entity to which BMXP has transferred ownership of the Registerable Securities in trust for the BMXP Record Shareholders.
 
NOTE 9. STOCK TRANSACTIONS

Transactions, other than employees' stock issuance, are in accordance with paragraph 8 of SFAS 123. Thus issuances shall be accounted for based on the fair value of the consideration received. Transactions with employees' stock issuance are in accordance with paragraphs (16-44) of SFAS 123. These issuances shall be accounted for based on the fair value of the consideration received or the fair value of the equity instruments issued, or whichever is more readily determinable.

On August 29, 2005 the Company split its common stock ten for one (10:1) from 1,278,000 to 12,780,000 shares outstanding. All stock transactions have been retroactively restated to reflect the ten for one stock split.

On October 6, 1998, the Company issued 1,000,000 shares of common stock for cash at $0.0001 per share.

On October 9, 1998, the Company issued 1,300,000 shares of common stock for cash at $0.001 per share.

On October 12, 1998, the Company issued 190,000 shares of common stock for cash at $0.001 per share.

On April 1, 1999, the Company issued 290,000 shares of common stock for cash at $0.001 per share.
 
On October 19, 1999, the Company issued 10,000,000 shares of common stock for cash at $0.01 per share.

On June 13, 2006 the Company cancelled 10,000,000 shares of common stock belonging to the Company’s former Chairman

On June 13, 2006 the Company issued 10,000,000 shares of common stock into Escrow in connection with the acquisition of BSMG.

On August 28, 2006 the Company issued 300,000 shares of common stock to consultants for services. Initially, 600,000 shares were issued in error, and 300,000shares were subsequently cancelled October 17, 2006.

On September 14, 2006 the Company issued 300,000 shares of common stock to management pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN

On September 14, 2006 the Company issued 5,000 shares of common stock to consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On October, 6, 2006 the Company issued 8,850 shares of common stock to consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On October 11, 2006 the Company issued 43,000 shares of common stock to consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On October 11, 2006, the Company shall issued 1,462,570 common shares of the Company to BMXP in full satisfaction of the amount of $1,191,619 plus accrued and unpaid interest, owed to BMXP Holdings, Inc. by the Company.
10
On November 10, 2006 the Company issued 100,000 shares of common stock to management pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.
 
On November 10, 2006 the Company issued 25,000 shares of common stock to consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On December 5, 2006 the Company issued 8,334 shares of common stock to a consultant for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On December 5, 2006 the Company issued 1,391,935 shares of common stock to Bio-Technology Partners Business Trust which constituted full satisfaction of the amount of $246,744 plus accrued interest owed by the Company to Bio-Technology Partners Business Trust.
 
On December 14, 2006 the Company issued 68,700 shares of common stock to management, employees and consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

During the quarter ended March 31, 2007 the Company issued 143,920 shares of common stock to management and employees as compensation pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

During the quarter ended March 31, 2007 the Company issued 359,310 to consultants for services pursuant to the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN.

On March 9, 2007 the Company issued 500,000 shares of common stock to Bio-Technology Partners Business Trust which constituted full satisfaction of the amount of $125,000 owed by the Company to Bio-Technology Partners Business Trust.

During the quarter ended March 31, 2007 the Company issued 500,000 shares of common stock for cash consideration of $125,000.

On April 4, 2007, the Company issued 240,666 common shares for cash consideration of $60,166.

On April 4, 2007, the Company issued 27,033 Shares to two purchasers as consideration for services rendered valued at $6,758.

On April 4, 2007, 985, 168 shares of the Company’s common stock were issued to Bombardier Pacific Ventures in full satisfaction of $246,292 owed by the Company to Bombardier Pacific Ventures. David R. Koos, the Company’s Chairman of the Board of Directors, President, CEO, Secretary, and Acting CFO, is the sole beneficial owner of Bombardier Pacific Ventures

NOTE 10. STOCKHOLDERS' EQUITY

The stockholders' equity section of the Company contains the following classes of capital stock as of March 31, 2007:

* Preferred stock, $ 0.0001 par value; 20,000,000 shares authorized: -0- shares issued and outstanding.

* Common stock, $ 0.0001 par value; 80,000,000 shares authorized: 17,996,619 shares issued and outstanding.

NOTE 11. COMMITMENTS AND CONTINGENCIES

On August 3, 2005, BMSG entered into an agreement to lease a 14,562 square foot facility for use as a cellular storage facility at a rate of:
$18,931 per month for the twelve months ended November 30, 2006,
$19,498 per month for the twelve months ended November 30, 2007,
$20,084 per month for the twelve months ended November 30, 2008,
$20,687 per month for the twelve months ended November 30, 2009, and
$21,307 per month for the twelve months ended November 30, 2010.
The lease is for a period of five years commencing on December 1, 2005 and expiring on November 30, 2010. The lease contains a renewal option enabling the Company to renew the lease for an additional five years. The Company is also responsible to pay its pro rata portion of common charges such as property taxes and insurance.
 
11
Minimum Lease Commitments
For the fiscal years ended on September 30,
 
2007
  
$
232,842
  
2008
  
$
239,936
  
2009
  
$
247,038
  
2010
  
$
254,444
  
2011
  
$
42,614
  
 
Since the signing of this lease, BMSG has been improving this facility and has made substantial progress toward creating a cGMP (Good Manufacturing Practices) and cGTP (Good Tissue Practices) compliant facility specifically designed for the cryogenic storage of stem cells, medical device engineering, stem cell research and stem cell specimen processing laboratories.
 
The Company expects to have the facility licensed by the State of California and registered with the FDA. Concurrently, the Company has been developing the policies and procedures needed for processing stem cells for cryogenic storage.

NOTE 12. ACQUISITION OF BIO-MATRIX SCIENTIFIC GROUP (NEVADA).

On June 14, 2006, the Company and Bio-Matrix Scientific Group, Inc., a Delaware corporation (the “Seller”) entered into a Stock Purchase Agreement (the “Acquisition Agreement”).

Under the terms of the Acquisition Agreement and pursuant to a separate Escrow Agreement between the Company and the Seller, The Company delivered to the Escrow Agent the sum of 10,000,000 shares of the Company’s common stock and other corporate and financial records and the Seller delivered to the Escrow Agent 25,000 shares of the common stock of BSMG., a Nevada corporation (the “Subsidiary”). As a part of the transaction and pursuant to the terms of the Acquisition Agreement and Stock Cancellation Agreement between the parties and John Lauring, the Company’s former Chairman and Chief Executive Officer, John Lauring returned 10,000,000 shares of the Company held and owned by him for cancellation.

On June 14, 2006, the Company’s officers and directors resigned their positions and elected Dr. David R. Koos and Mr. Brian Pockett as in-coming Directors of the Registrant. Following their election and the reconstruction of the Board of Directors, the Registrant’s Board of Directors elected Dr. David R. Koos as Chief Executive Officer and President and Mr. Brian Pockett as Chief Operating Officer and Vice President on June 19, 2006.

On July 3, 2006, the Acquisition Agreement closed and Company acquired the twenty-five thousand (25,000) shares of the Common Stock of the Subsidiary from the Seller in exchange for the payment of the purchase price of 10,000,000 shares of the common stock of the Company and the 10,000,000 shares of the Company owned and held by John Lauring were returned to the Company for cancellation. At that time, the Escrow Agent released all stock certificates and certain other corporate and financial books and records held pursuant to the Escrow Agreement.
 
As a result of the Acquisition Agreement, the Subsidiary became a wholly owned subsidiary of the Company and the Seller became the holder of approximately 78.24% of the outstanding common stock of the Registrant.

On July 3, 2006, the Company changed its principal offices from 23 Brigham Road, Worcester MA 01609 to 8885 Rehco Road, San Diego, California 92121

NOTE 13. TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATION PLAN

On July 25, 2006 the Company adopted the TASCO HOLDINGS INTERNATIONAL, INC. 2006 EMPLOYEE AND CONSULTANTS STOCK COMPENSATIONPLAN (“the Plan”) which provides for the issuance of up to 1,500,000 authorized but unissued shares of Common Stock to eligible employees and consultants for services rendered (“Award Shares” or “Awards”). These Award Shares were registered with the Securities and Exchange Commission (“Commission”) on Form S-8 filed with the Commission on August 8, 2006. This Plan shall terminate on July 15, 2016.

Award Shares may be issued to Eligible Persons (The term "Eligible Person" means any natural person who, at a particular time, is an employee, officer, director, consultant, or advisor of the Company or any Parent or Subsidiary of the Company; provided that, in the case of consultants or advisors such services are not in connection with the offer and sale of securities in a capital-raising transaction and /or such services are not intended to directly or indirectly promote or maintain a market for the Company ’s securities) in any of the following instances:
 
(i) as a bonus for services previously rendered and compensated, in which case the recipient of the Award Shares shall not be required to pay any consideration for such Award Shares, and the value of such Award Shares shall be the Fair Market Value of such Award Shares on the date of grant; or

(ii) as compensation for the previous performance or future performance of services or attainment of goals, in which case the recipient of the Award Shares shall not be required to pay any consideration for such Award Shares (other than the prior performance of his services or the assumption of the obligation of future performance of services ).
12
The Plan is currently administered by the Plan Committee, which currently consists of the entire Board of Directors of the Company, and which has sole and absolute discretion to interpret and determine the effect of all matters and questions relating to this Plan.

The Plan Committee has the full and final authority in its sole discretion, at any time and from time-to-time, subject only to the express terms, conditions and other provisions of the Articles of Incorporation of the Company and this Plan, and the specific limitations on such discretion set forth herein, to:

(i) Designate the Eligible Persons or classes of Eligible Persons eligible to receive Awards from among the Eligible Persons;

(ii) Grant Awards to such selected Eligible Persons or classes of Eligible Persons in such form and amount (subject to the terms of the Plan) as the Plan Committee shall determine;

(iii) Interpret the Plan, adopt, amend and rescind rules and regulations relating to the Plan, and make all other determinations and take all other action necessary or advisable for the implementation and administration of the Plan; and

(iv) Delegate all or a portion of its authority to one or more directors of the Company who are executive officers of the Company, subject to such restrictions and limitations (such as the aggregate number of shares of Common Stock that may be awarded) as the Plan Committee may decide to impose on such delegate directors.
 
As of March 31, 2007 -- 1,362,114 shares have been issued pursuant to the Plan
 
 
   
Number of 
  
 
   
Shares
  
As of March 31, 2007:
    
 
       
   
 
Granted
    
1,362,114*
  
Remaining shares available for issuance under the Plan as of March 31, 2007
   
137,886
  
 
*Does not include 300,000 shares which were issued erroneously and subsequently cancelled

NOTE 14. SUBSEQUENT EVENTS.-

On April 4, 2007, the Company issued 240,666 common shares (“Shares”) for cash consideration of $60,166.

The net proceeds of the sale of shares sold for cash consideration, which were $60,166, will be utilized for general working capital purposes.

On April 4, 2007, the Company issued 27,033 Shares to two purchasers as consideration for services rendered valued at $6,758.

On April 4, 2007, 985, 168 shares of the Company’s common stock were issued to Bombardier Pacific Ventures in full satisfaction of $246,292 owed by the Company to Bombardier Pacific Ventures. David R. Koos, the Company’s Chairman of the Board of Directors, President, CEO, Secretary, and Acting CFO, is the sole beneficial owner of Bombardier Pacific Ventures
 
Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN FORWARD-LOOKING INFORMATION

Information provided in this Quarterly report on Form 10QSB may contain forward-looking statements within the meaning of Section 21E or Securities Exchange Act of 1934 that are not historical facts and information. These statements represent the Company's expectations or beliefs, including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company's operations, economic performance, financial conditions, margins and growth in sales of the Company's products, capital expenditures, financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. The Company's financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company with the Securities and Exchange Commission, including the Company's most recent Form 10KSB for the year ended September 30, 2006.
13
CONDITION AND RESULTS OF OPERATIONS THREE MONTHS ENDED MARCH 31, 2007

Revenues were -0- for the quarter ending March 31, 2007 and -0- for the same quarter ending March 31, 2006. Net loss were $515,624 for the three months ended March 31, 2007 and $1,632 for the same period ended March 31, 2006.
 
ACQUISITION OF WHOLLY OWNED SUSIDIARY

As of the acquisition of 100% of the share capital of Bio-Matrix Scientific Group, Inc. (“BMSG”, a Nevada corporation) on July 3, 2006, Tasco Holdings International, Inc. (“Company”) has ceased all activities relating to its historical business and adopted the business plan of BMSG.

BMSG is developmental stage company engaged primarily in the cryogenic storage of stem cells and the development of medical devices used in live tissue transfer and stem cell research.

Through BMSG, the Company has developed a line of medical devices (approximately 192 disposable instruments for use in the plastic surgery field and stem cell research). The instruments are designed to be used to harvest adult stem cells from adipose (fat) tissue. The Company seeks to market and sell these instruments to plastic surgeons and to offer the patients of these plastic surgeons an opportunity to store stem cells derived from adipose tissue for future medical treatments. The Company has not conducted or obtained any independent evaluation of the efficacy or likely market interest in using these instruments. The Company's evaluations have been limited to those conducted by Company management without the benefit of any independent or third party professional evaluation.

Through BMSG , the Company is currently constructing what it believes is a state-of-the art, FDA good manufacturing practices (cGMP) and good tissue practices (cGTP) compliant facility for the processing and cryo-storage (in liquid nitrogen) of adult stem cells. It anticipates that it will offer a similar service to expectant parents by offering to store their newborn's cord blood stem cells as well. In undertaking these plans, it intend to offer such storage services at its planned facility. The planned facility is located at 8885 Rehco Road, San Diego, California 92121 and has approximately 15,000 square feet. The planned facility was acquired under a five year lease on December 1, 2005 at a current cost of $18,931 per month (plus certain common area costs). Under the terms of the lease, the lease term may be extended for an additional five year lease term at the then prevailing market prices.

All of the Company's current plans and strategy have been developed solely by our officers and Directors.

PLAN OF OPERATION

As of March 31, 2007 the Company has $147,705 cash on hand and current liabilities of $353,310 such liabilities consisting of Accounts Payable, Notes Payable, Accrued Payroll Taxes, and Accrued Interest.
 
The Company feels it will not be able to satisfy its cash requirements over the next twelve months and shall be required to seek additional financing.
  
At this time, the Company plans to fund its financial needs through operating revenues (which cannot be assured) and, if required, through equity private placements of common stock. (No plans, terms, offers or candidates have yet been established and there can be no assurance that the company will be able to raise funds on terms favorable to the Company or at all.) During the period beginning January 1, 2007 and ending April 4, 2007, the Company sold 1,752,867 shares of common stock at a purchase price of $0.25 per share.

740,666 of the Shares were sold for cash consideration of $185,166 to five purchasers.
The net proceeds of the sale of shares sold for cash consideration, which were $185,166, will be utilized for general working capital purposes. We estimate that these net proceeds will not be sufficient to fulfill our capital needs through the next twelve months.
 
27,033 of the Shares were issued to two purchasers as consideration for services rendered valued at $6,758.

985, 168 of the Shares were issued to Bombardier Pacific Ventures in full satisfaction of $246,292 owed by the Company to Bombardier Pacific Ventures on April 4, 2007.

Over the next 12 months, the Company anticipates opening its stem cell bank and marketing its disposable stem cell / tissue management instruments. Furthermore, the Company expects to increase the total number of employees by 20 new hires.
14
Item 3. CONTROLS AND PROCEDURES
 
(A) Evaluation of Disclosure Controls and Procedures
 
As of the end of the period covered by this report, the Company carried out an evaluation, under the supervision and with the participation of David Koos, who is the Company's Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. The Company's disclosure controls and procedures are designed to provide a reasonable level of assurance of achieving the Company's disclosure control objectives. The Company's Principal Executive Officer/Principal Financial Officer has concluded that the Company's disclosure controls and procedures are, in fact, effective at this reasonable assurance level as of the period covered.
 
(B) Changes in Internal Controls over Financial Reporting
 
In connection with the evaluation of the Company's internal controls during the period commencing on January 1, 2007 and ending March 31, 2007, David Koos, who is both the Company's Principal Executive Officer and Principal Financial Officer has determined that there are no changes to the Company's internal controls over financial reporting that has materially affected, or is reasonably likely to materially effect, the Company's internal controls over financial reporting.
 
PART II.
 
Item 1: LEGAL PROCEEDINGS

None

Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

On March 9, 2007 the Company issued 500,000 shares of common stock to Bio-Technology Partners Business Trust which constituted full satisfaction of the amount of $125,000 owed by the Company to Bio-Technology Partners Business Trust.

No underwriters were retained to serve as placement agents for the sale. The 500,000 shares of common stock were sold directly through the management of the Company. No commission or other consideration was paid in connection with the sale of the 500,000 shares of common stock.

The offer and sale of the 500,000 shares of common stock was exempt from the registration provisions of the Securities Act of 1933, as amended, by reason of Section 4(2) thereof.

During the period beginning January 1, 2007 and ending April 4, 2007, the Company sold 1,752,867 restricted shares (the "Shares") of common stock, at a purchase price of $0.25 per share.

740,666 of the Shares were sold for cash consideration of $185,166 to five purchasers.
The net proceeds of the sale of shares sold for cash consideration, which were $185,166, will be utilized for general working capital purposes. The Company estimates that these net proceeds will not be sufficient to fulfill our capital needs through the next twelve months.

27,033 of the Shares were issued to two purchasers as consideration for services rendered valued at $6,758.

985, 168 of the Shares were issued to Bombardier Pacific Ventures in full satisfaction of $246,292 owed by the Company to Bombardier Pacific Ventures on April 4, 2007. David R. Koos, the Company’s Chairman of the Board of Directors, President, CEO, Secretary, and Acting CFO, is the sole beneficial owner of Bombardier Pacific Ventures.

No underwriters were retained to serve as placement agents for the sale. The Shares were sold directly through the management of the Company. No commission or other consideration was paid in connection with the sale of the Shares

The offer and sale of the Shares was exempt from the registration provisions of the Securities Act of 1933, as amended, by reason of Section 4(2) thereof.
15
Item 3. DEFAULTS UPON SENIOR SECURITIES

None.
 
Item 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

None.
 
Item 5. OTHER INFORMATION

None.
 
Item 6. EXHIBITS
 
31.1
Certification of Chief Executive Officer
 
 
31.2
Certification of Acting Chief Financial Officer
 
 
32.1
Certification of Chief Executive Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
 
 
32.2
Certification of Acting Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
 

 


SIGNATURES

In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 

 
Bio Matrix Scientific Group, Inc.
 
a Delaware corporation
 
 
By: 
/s/ David R. Koos
 
David R. Koos 
 
Chief Executive Officer
 
Date: March 10, 2007
 
 
16